Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double‐Blind Phase II Trial Authors: Ping Jin, Linong Ji, Yangqing Huang, Haifeng Ding, Daosheng Xie, Xiaohui Jiang, Xuemei Yuan, Zhao Cao, Haibin Zhang, Jiandong Yuan Published: 2026 ABSTRACT ABSTRACTAimThis study aimed to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in Chinese adults with T2DM and to preliminarily compare its efficacy and safety with semaglutide through multiple subcutaneous injections.Materials and MethodsIn this multicentre, randomised, placebo‐controlled and semaglutide‐positive‐controlled trial, 64 Chinese adults with T2DM were randomly assigned to BGM0504 5 mg (n = 12), 10 mg (n = 12), 15 mg (n = 12), placebo (n = 12) or semaglutide 1 mg (n = 16). All participants received their assigned dose once weekly for 12 weeks. The primary endpoint was the change in HbA1c from baseline, and secondary endpoints included fasting plasma glucose (FPG), 2‐h plasma glucose (2 h PG) and body weight. Safety was assessed through adverse events, laboratory tests and vital signs.ResultsAt Week 12, the mean changes in HbA1c from baseline were −1.72% for the 5 mg dose, −1.94% for the 10 mg dose, −2.48% for the 15 mg dose, −1.43% for 1 mg semaglutide and 0.28% for placebo, with the treatment differences versus placebo (LSM) ranging from −1.82% to −2.56% (all p < 0.05). The proportion of participants achieving HbA1c < 6.5% or < 7.0% increased in a dose‐dependent manner. BGM0504 also shows a signal for lowering FPG, 2 h PG and body weight (all p < 0.05), with the 15 mg dose showing superior weight reduction to semaglutide. Pharmacokinetics analysis confirmed a linear exposure–response relationship. All doses were well tolerated, with mostly mild adverse events.ConclusionBGM0504 shows a signal reduction for HbA1c, FPG, 2 h PG and body weight in Chinese adults with T2DM. The 12‐week treatment with BGM0504 was safe and well‐tolerated, with the 15 mg dose showing the most substantial effects. Introduction Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease primarily characterised by hyperglycaemia, resulting from insulin resistance and/or insufficient insulin secretion. Prolonged hyperglycaemia can lead to microvascular and macrovascular complications, significantly increasing the risks of disability and mortality [1]. Over the past decades, the prevalence of T2DM has risen sharply in China due to ageing populations and lifestyle changes [2, 3]. Obesity, a major modifiable risk factor for T2DM, is closely associated with insulin resistance, a key feature of its pathogenesis and a significant barrier to achieving glycaemic control [4]. The interplay between chronic hyperglycaemia, glucotoxicity and pancreatic β‐cell dysfunction creates a vicious cycle that exacerbates insulin deficiency and metabolic deterioration. Effective management of T2DM therefore requires a combination of dietary and lifestyle interventions to promote weight loss, alongside pharmacological treatments to control hyperglycaemia and optimise metabolic parameters such as blood pressure and lipid levels [5, 6]. GLP‐1 receptor agonists (GLP‐1RAs) have been shown to effectively control blood glucose, reduce body weight and improve cardiovascular risk factors, with demonstrated benefits in mitigating microvascular and macrovascular complications [7, 8, 9, 10, 11]. While GLP‐1RAs have established their role in the treatment of T2DM [12], many patients still fail to achieve their glycaemic targets. Therefore, improvements to GLP‐1RAs are needed to enhance their glucose‐lowering and weight‐reducing effects, addressing unmet clinical needs. One emerging approach involves combining GLP‐1RAs with therapies targeting other pathways involved in nutrition and energy metabolism, such as glucose‐dependent insulinotropic polypeptide (GIP). Eli Lilly's investigational GIP/GLP‐1 dual receptor agonist, Tirzepatide (brand name: MOUNJARO), has demonstrated superiority over the GLP‐1RA semaglutide in lowering glucose levels and reducing body weight in patients with diabetes [13]. As approved by the FDA in May 2022 for glycaemic control in adults with type 2 diabetes, Tirzepatide has also undergone multi‐regional Phase III clinical trials for weight management in overweight and obese populations [14]. Meanwhile, multiple GLP‐1R/GIPR dual agonists are in various development stages for indications including T2DM, obesity, non‐alcoholic steatohepatitis (NASH) and cardiovascular risk [11, 15, 16]. BGM0504 injection is a novel peptide‐based GLP‐1R/GIPR dual agonist formulated for weekly administration. The previous study has revealed favourable salt bridge interactions between the K20 residue of the parent peptide and acidic residues in the extracellular domains of both GLP‐1R and GIPR, which are critical for full receptor activation. Guided by this mechanistic insight, the acylation strategy was optimised to preserve these interactions, resulting in the design of BGM0504. This optimised peptide was reported to have enhanced agonistic activity compared with tirzepatide in preclinical assays [17]. Building on these preclinical findings, a Phase Ia clinical trial in healthy volunteers confirmed linear dose‐proportional pharmacokinetics (PKs) from 2.5 to 15 mg, with the 15 mg dose advancing to subsequent studies. In this paper, we present the investigation of a Phase II study that was randomised and double‐blind with placebo control and included an open‐label semaglutide positive control arm to evaluate the safety, tolerability, PK/PD profile, efficacy and immunogenicity of BGM0504 in patients with diabetes. Materials and Methods Overview The study was conducted in compliance with local regulations, the Good Clinical Practice (GCP) guidelines from the International Conference on Harmonisation and the ethical principles outlined in the Declaration of Helsinki [18]. Ethics committees at all study sites, including Central South University Xiangya Third Hospital; The Fourth Affiliated Hospital of Harbin Medical University; Hebei CNPC Central Hospital; The First Affiliated Hospital of Henan University of Science and Technology, Luoyang; Third People's Hospital, Xuzhou Medical University Affiliated Hospital, Changsha; Third Hospital, Huizhou Central People's Hospital; Chenzhou First People's Hospital and Nanyang Medical Higher College First Affiliated Hospital, approved the study protocol and informed consent form. The study was registered at ClinicalTrails.gov (NCT06974825). All participants provided written informed consent before being enrolled in the study. The trial was conducted between 30 August 2023 and 13 August 2024. Study Design This randomised, controlled and double‐blind Phase II study aimed to evaluate the safety, tolerability and PK/PD of BGM0504 in Chinese adults with type 2 diabetes. The study consists of three double‐blind BGM0504 dose groups (5, 10 and 15 mg), each including a placebo arm and an open‐label semaglutide positive control group. The study included a 2‐week screening, a 14–16 week double‐blind treatment period and a 2‐week follow‐up. The treatment period was divided into two stages: a 2‐ to 6‐week titration phase followed by 4 weeks of target dose treatment in Stage 1 and 8 weeks of continued target dose treatment in Stage 2. Study grouping information can be found in Appendix SH. Study participants were randomised into one of three dose groups or a positive control group receiving semaglutide (1 mg). Each treatment group consisted of 16 participants (12 on BGM0504, 4 on placebo; the resulting 12 participants in the placebo group were pooled for analysis). The study was completed with a database lock on 21 August 2024. Procedures In the first stage of the treatment period, BGM0504 and placebo were injected once weekly, with each dose group titrated to the target dose. The 5 mg group received two 2.5 mg titration doses; the 10 mg group received four titration doses (2.5 mg for 2 weeks, then 5 mg for 2 weeks); the 15 mg group received six titration doses (2.5 mg for 2 weeks, 5 mg for 2 weeks, then 10 mg for 2 weeks). A schematic diagram of the study design can be found in Appendix SG. After reaching the target dose, it was continued for an additional 4 weeks. In the second stage, the target dose was maintained once per week for 8 weeks. The open‐label, positive control group received once‐weekly semaglutide, with six titration doses (0.25 mg for 3 weeks, then 0.5 mg for 3 weeks) in the titration period and a subsequent treatment period of 1 mg for 12 weeks. The final follow‐up included a 2‐week safety monitoring period. Participants Eligible participants were adults aged 18–65 years with T2DM diagnosed per 1999 WHO criteria (HbA1c ≥ 6.5% as a complementary criterion). Participants either were newly diagnosed and had undergone ≥ 8 weeks of diet and exercise intervention without prior antidiabetic medication or had a previous diagnosis of T2DM with no diabetes medication within 8 weeks before screening and continued diet/exercise intervention. All participants had a body mass index (BMI) of 19.5–35.0 kg/m2, HbA1c of 7.0%–10.0% and fasting plasma glucose of ≤ 13.3 mmol/L. Written informed consent was obtained. The main exclusion criteria were participants who had experienced severe acute diabetic complications within the last 12 months; had severe chronic diabetic complications at screening; had other severe endocrine diseases affecting glucose metabolism; had the following cardiovascular diseases in the last 6 months: heart failure (NYHA Classes III and IV), myocardial infarction, coronary artery bypass grafting (CABG) and severe arrhythmias; had thyroid dysfunction; had uncontrolled hypertension; had a medical history of acute or chronic pancreatitis; had a medical history or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2; a had medical history of blood disorders or diseases that may affect HbA1c testing results; had been diagnosed with malignant tumours within the last 5 years; had severe psychiatric disorders; allergic to GLP‐1RAs. Full inclusion and exclusion criteria are listed in Appendix SF. Randomisation The trial enrolled 64 patients with T2DM, with 16 subjects per dose group in the 5, 10 and 15 mg dose groups (randomly assigned to either the BGM0504 injection group or the placebo group in a ratio of 12:4). A total of 16 subjects were enrolled in the positive control group, all of whom were given semaglutide injection. The randomisation list was generated by an independent statistician who was blind to the clinical operations of the study. The trial used a Randomisation and Trial Supply Management (RTSM) system to assist with central randomisation, blinding implementation and the distribution and management of study drugs. The study drugs and their matching placebos were identically labelled and indistinguishable in appearance. Both participants and investigators, along with study site personnel involved in treating and assessing participants, as well as sponsor personnel in contact with the investigators and participants, were blinded to the treatment allocation until the database was locked for the first part of the study. Other sponsor personnel remained blinded until all participants in the first part had completed. PK and Pharmacodynamic (PD) Evaluation Blood samples were collected from the treatment and placebo‐controlled groups for PK evaluation. Approximately 4 mL of blood was collected via venous indwelling needles or venepuncture. Samples were collected within 1 h prior to the first, third and fifth titration injections (once for the 5 mg dose group, twice for the 10 mg dose group and three times for the 15 mg dose group). Additionally, samples were collected before and after the target dose injections at several time points. For the first target dose injection, blood was collected 1 h before the injection and then at 2, 4, 8, 12, 24, 36, 48, 72, 120 and 168 h (just before the second target dose injection). For the third and fourth target dose injections, samples were collected 1 h before the injection. After the fourth target dose injection, samples were taken at 2, 4, 8, 12, 24, 36, 48, 72, 120 and 168 h (just before the fifth target dose injection). Finally, for the 9th and 12th target dose injections, blood was collected 1 h before each injection. Efficacy was evaluated using primary and secondary PD endpoints. The primary PD endpoint was the change in HbA1c from baseline at the 12th week of target dose injection. Secondary PD endpoints included changes from baseline in fasting plasma glucose (FPG), 2‐h plasma glucose (2 h PG) and body weight. Statistical Analysis The population baseline characteristics and dropouts were evaluated in the Full Analysis Set (FAS), defined as all randomised participants who received at least one dose of the study drug. PKs were assessed in two subsets: the PK concentration set (PKCS), which includes participants who received at least one dose of the study drug and have at least one valid drug concentration result and the PK parameter set (PKPS), which includes participants with sufficient concentration data to obtain at least one PK parameter. PD was evaluated in the pharmacodynamics set (PDS), which includes participants who received the study drug without significant protocol deviations affecting PD parameters and who have at least one evaluable PD parameter. Safety was assessed in the safety set (SS), defined as participants who were randomised and received at least one dose of the study drug. The SS was used for safety analyses, with all analyses conducted according to the actual treatment groups. The PK parameters for BGM0504 injection were calculated using non‐compartmental analysis (NCA) with WinNonlin V8.4 or higher versions. The relationship between the primary PK parameters (C max, AUC0–t , AUCinf) and dose was analysed using a power model: lnPK=β0+β1lnD, where β1 represented the deviation from dose linearity for plasma BGM0504 concentration. The point estimate of β1 and its 90% confidence interval (CI) was calculated. Statistical analyses of changes from baseline in efficacy endpoints were performed in the PDS using analysis of covariance (ANCOVA) models. The primary endpoint, change in HbA1c from baseline at Week 12 of target‐dose administration, was analysed with treatment group as a fixed effect and baseline HbA1c as a covariable, with missing data imputed using the last observation carried forward (LOCF) method. The same statistical analysis approach was applied to key secondary efficacy endpoints, including changes in HbA1c, FPG, 2 h PG and body weight at prespecified visits. The proportions of participants achieving HbA1c < 7.0% and < 6.5% at Week 12 and other secondary endpoints were summarised descriptively. A simple linear regression model was also constructed with the change in HbA1c from baseline at Week 12 post‐dose as the dependent variable and dose groups as the independent variable. Safety was evaluated based on adverse events (AEs), laboratory tests, vital signs, physical examinations, 12‐lead electrocardiograms (ECGs), hypoglycaemic events and injection site reactions. Descriptive statistics were performed for these safety parameters. All AEs were coded using the Chinese version of the Medical Dictionary for Regulatory Activities (MedDRA), classified by System Organ Class (SOC) and Preferred Term (PT) and summarised by treatment group. Results Participants' Demographics and Baseline Characteristics As presented in Figure 1, a total of 64 subjects were enrolled in the study between 30 August 2023 and 13 August 2024, with 33 males (51.6%) and 31 females (48.4%). They were randomly assigned to five groups with 12 subjects in the BGM0504 5 mg group, 12 in the BGM0504 10 mg group, 12 in the BGM0504 15 mg group, 16 in the positive control group and 12 in the placebo group. The FAS, PPS, SS and PDS included the same set of subjects. The PKCS, which was used for PK concentration analysis, included 36 subjects: 12 in each of the BGM0504 5, 10 and 15 mg groups. The PKPS, used for PK parameter analysis, included 35 subjects: 12 in the 5 mg group, 12 in the 10 mg group and 11 in the 15 mg group (after excluding one missing). The placebo group was excluded from the PK analysis. The mean age of the participants was 50.1 ± 10.14 years, with a range of 24–65 years. The mean BMI was 27.8 ± 2.90 kg/m2, ranging from 21.10 to 34.80 kg/m2. The mean weight was 76.2 ± 12.39 kg, with a range of 49.4–107.1 kg. Baseline characteristics were balanced between treatment groups, as summarised in Table 1. Trial profile. One subject in each of the 5 mg dose group, 15 mg dose group and placebo group withdrew early without receiving medication after randomisation (all subjects withdrew voluntarily). TABLE 1Baseline demographics and clinical characteristics.5 mg BGM0504 (N = 12)10 mg BGM0504 (N = 12)15 mg BGM0504 (N = 12)Semaglutide (N = 16)Placebo (N = 12)Demographic characteristicsAge (years)56.0 (6.78)51.4 (11.29)46.4 (10.36)48.3 (9.18)48.8 (11.45)SexMale5 (41.7)1 (8.3)7 (58.3)11 (68.8)9 (75.0)Female7 (58.3)11 (91.7)5 (41.7)5 (31.3)3 (25.0)BMI distributionBMI < 2812 (100.0)6 (50.0)3 (25.0)8 (50.0)7 (58.3)BMI ≥ 2806 (50.0)9 (75.0)8 (50.0)5 (41.7)BMI (kg/m2)25.1 (2.11)27.3 (1.67)29.7 (2.94)28.6 (2.30)28.1 (3.46)Weight (kg)68.8 (13.00)69.3 (10.57)84.2 (8.55)79.5 (11.42)78.3 (12.07)Clinical characteristicsHbA1c (%)8.3 (0.83)8.1 (0.85)8.3 (0.99)7.8 (0.97)8.0 (0.82)Fasting insulin87.4 (62.91)78.1 (28.90)117.6 (76.50)092.5 (85.91)Fasting C‐peptide827.1 (252.57)742.8 (187.79)999.9 (299.20)962.3 (284.22)797.6 (495.47)Fasting glucagon423.6 (292.18)417.6 (205.28)929.8 (1308.06)0398.1 (303.55)Fasting proinsulin200.8 (83.91)191.3 (64.73)216.7 (90.19)112.4 (0.00)194.7 (103.64)Fasting plasma glucose9.7 (1.87)9.7 (1.33)10.7 (2.03)9.3 (2.03)9.6 (2.22)2 h postprandial glucose17.0 (3.73)17.3 (3.96)17.7 (2.46)15.7 (4.01)17.7 (3.53)Fasting weight (kg)68.2 (11.36)68.9 (14.93)85.7 (8.92)77.1 (9.95)71.5 (8.61)Time since first diagnosis of diabetes (years)4.7 (4.73)3.9 (3.35)1.8 (1.42)1.9 (1.93)2.4 (2.15)Historical characteristicsPrevious and concomitant drug treatmentsYes9 (75.0)8 (66.7)9 (75.0)13 (81.3)8 (66.7)No3 (25.0)4 (33.3)3 (25.0)3 (18.8)4 (33.3)Previous and concomitant non‐drug treatmentsYes2 (16.7)1 (8.3)000No10 (83.3)11 (91.7)12 (100.0)16 (100.0)12 (100.0)Surgical historyHistory of surgery3 (25.0)9 (75.0)7 (58.3)5 (31.3)3 (25.0)No history of surgery9 (75.0)3 (25.0)5 (41.7)11 (68.8)9 (75.0)Smoking historyNever smoked10 (83.3)12 (100.0)10 (83.3)9 (56.3)9 (75.0)Former smoker0001 (6.3)1 (8.3)Current smoker2 (16.7)02 (16.7)6 (37.5)2 (16.7)Alcohol consumption historyNever10 (83.3)12 (100.0)10 (83.3)12 (75.0)7 (58.3)Former drinker00002 (16.7)Current drinker2 (16.7)02 (16.7)4 (25.0)3 (25.0) Note: Continuous variables are presented as mean (SD); categorical variables are presented as n (%). Baseline demographics and clinical characteristics. Note: Continuous variables are presented as mean (SD); categorical variables are presented as n (%). PKs' Analysis The plasma concentrations of BGM0504 in the 5, 10 and 15 mg dose groups were examined. The mean concentration semi‐logarithmic time curve is shown in Figure 2. In T2DM subjects, BGM0504 injection at doses of 5, 10 and 15 mg, injected once weekly, reached peak plasma concentrations around 24 h post‐dose. After the fourth dose at the target dose, the elimination half‐life was approximately 109–160 h. Mean concentration logarithmic time curve. After the first target dose and the fourth target dose at steady state, the main PK parameters of BGM0504, including C max, were analysed. The point estimate and 90% CI for the slope of C max were 0.92 (0.79, 1.05). For AUC0–168, the point estimate and 90% CI for the slope were 0.90 (0.72, 1.08) and for AUC0–inf, the point estimate and 90% CI for the slope were 0.94 (0.79, 1.08). The 90% CI for C max, AUC0–168 and AUC0–inf included 1, suggesting that C max, AUC0–168 and AUC0–inf exposure had a typical linear relationship with the dose (Appendix SC.1). After the fourth target dose was stabilised, the point estimate and 90% CI for the slope of C max,ss was 0.65 (0.45, 0.85); the point estimate and 90% CI for the slope of AUC0–168 was 0.78 (0.58, 0.97); the point estimate and 90% CI for the slope of AUC0–inf was 0.92 (0.69, 1.50). After the fourth target dose was stabilised, C max,ss and AUC0–168 exposure had a non‐typical linear relationship, and AUC0–inf showed a typical linear relationship (Appendix SC.2). PD Analysis At Week 12, reductions in HbA1c from baseline were observed across all treatment groups (Table 2 and Figure 3A). The mean changes in HbA1c were as follows: a reduction of −1.72% (SD 0.99%) for the 5 mg dose, −1.94% (1.35%) for the 10 mg dose, −2.48% (0.90%) for the 15 mg dose, −1.43% (1.17%) for the 1 mg semaglutide group and +0.28% (1.65%) for the placebo group (Figure 2A). The least squares mean (LSM) treatment differences versus placebo ranged from −1.82% to −2.56% for the BGM0504 doses and semaglutide (all p < 0.05). The 15 mg dose of BGM0504 showed a reduction in HbA1c to semaglutide (p = 0.0327), indicating that BGM0504 at this dose may offer better efficacy in lowering HbA1c than the active comparator. The results were illustrated in Appendix SA.1. TABLE 2Summary of changes in HbA1C from baseline at Week 12‐PDS.Analysis variable5 mg BGM0504 (N = 13)10 mg BGM0504 (N = 11)15 mg BGM0504 (N = 12)Semaglutide (N = 16)Placebo (N = 12)HbA1C (%)Baseline8.200 (0.8134)8.191 (0.8689)8.267 (0.9921)7.781 (0.9683)7.983 (0.8178)Week 126.485 (0.6768)6.255 (1.1121)5.783 (0.6279)6.350 (0.8687)8.258 (1.5670)Relative change from baseline at Week 12−1.72 (0.989)−1.94 (1.354)−2.48 (0.899)−1.43 (1.167)0.28 (1.645)Within group LsMeansLsMeans diff−1.72−1.94−2.48−1.430.2895% CI[−2.31, −1.12][−2.85, −1.03][−3.05, −1.91][−2.05, −0.81][−0.77, 1.32] p < 0.00010.0008< 0.00010.00020.5743Between groups LsMeansLsMeans diff−1.82−2.05−2.56−1.8695% CI[−2.83, −0.81][−3.27, −0.82][−3.58, −1.54][−2.83, −0.90] p 0.00110.0023< 0.00010.0005 Note: Values for HbA1C are shown as mean (SD). Change in HbA1c from baseline at Week 12 was calculated using analysis of covariance (ANCOVA) models with treatment group as a fixed effect and baseline HbA1c as a covariable.Abbreviations: CI, confidence interval; LsMeans, least squares means. Summary of changes in HbA1C from baseline at Week 12‐PDS. Note: Values for HbA1C are shown as mean (SD). Change in HbA1c from baseline at Week 12 was calculated using analysis of covariance (ANCOVA) models with treatment group as a fixed effect and baseline HbA1c as a covariable. Abbreviations: CI, confidence interval; LsMeans, least squares means. Changes in HbA1c, fasting plasma glucose (FPG), body weight and 2‐h plasma glucose (2 h PG) over time; proportion of participants achieving HbA1c. (A) Change from baseline in HbA1c over time. (B) Change from baseline in FPG over time. (C) Change from baseline in weight loss over time. (D) Change from baseline in 2 h PG over time. (E) Proportion of participants reaching HbA1c targets. Data in (A–D) are plotted as least squares mean ± SD from an ANCOVA analysis of the PDS population. The proportion of participants reaching HbA1c was obtained by dividing the number of participants reaching the respective target at Week 12 by the number of participants in the PDS population. Participants' numbers were as follows: 5 mg BGM0504 n = 13, 10 mg BGM0504 n = 11, 15 mg BGM0504 n = 12, placebo n = 12 and semaglutide n = 16. In terms of achieving specific HbA1c targets, the percentage of participants achieving HbA1c < 6.5% was 37.18% for the 5 mg dose, 46.97% for the 10 mg dose, 75.00% for the 15 mg dose and 58.33% for semaglutide, compared to 0% in the placebo group. Differences were observed for the 10, 15 mg and semaglutide groups compared to placebo (all p < 0.05). Similarly, the percentage of participants achieving HbA1c < 7.0% was 60.26% for the 5 mg dose, 65.15% for the 10 mg dose, 75.00% for the 15 mg dose and 58.33% for semaglutide, compared to 0% in the placebo group. All these differences were significant (p < 0.05) (Appendix SB and Figure 3E). Key secondary efficacy results showed significant reductions in FPG: −2.05 mmol/L (SD 1.82), −2.52 mmol/L (2.69) and −4.00 mmol/L (1.52) at doses of 5, 10 and 15 mg, respectively. The treatment difference versus placebo (LSM) ranged from −3.18 to −1.63 mmol (all p < 0.05) (Appendix SA.3 and Figure 3B). The 2 h PG were reduced by −7.18 mmol/L (3.59), −7.17 mmol/L (6.84) and −8.73 mmol/L (2.59) for the 5, 10 and 15 mg doses, respectively, with treatment difference versus placebo (LSM) ranging from −6.16 to −4.76 mmol/L (all p < 0.05) (Appendix SA.4 and Figure 3D). The change in systolic blood pressure from baseline at Week 12 for the 15 mg group was −10.73 mmHg (p < 0.05), and no notable changes were observed in the other dose groups or the placebo/semaglutide groups (Appendix SA.5). After 12 weeks of treatment, no significant change in body weight was observed in the BGM0504 5 mg group. However, the 10 and 15 mg groups showed mean weight reductions of −4.83 kg (SD 4.50) and −8.25 kg (SD 3.83), respectively, both greater than placebo. The percentage change in body weight reduction from baseline was also greater in the 10 and 15 mg groups than in the placebo, with LSM differences of −6.58% and −9.55%, respectively (p < 0.01). The positive control group had an LSM of −2.34%, which was not different from placebo (p = 0.09). When compared with the positive control, LSM differences in percentage weight change were 2.41, −3.77 and −7.15 for the 5, 10 and 15 mg groups, respectively, with a difference observed for the 15 mg group (p < 0.005) (Appendix SA.2 and Figure 3C). Linear regression analysis was performed for the change of HbA1c from baseline to target dose after 12 weeks of treatment. The 12‐week HbA1c changes from baseline fell within the 90% predicted CI of the linear regression model, and it was close to the regression line, so the effect of 5, 10 and 15 mg doses and 12 weeks of HbA1c change from baseline was linear, as illustrated in Appendix SE. Safety Analysis A total of 64 subjects were included in the safety analysis set (SS), and 56 subjects (87.5%) experienced 181 treatment‐emergent AEs (TEAEs). In the BGM0504 5 mg group, 12 subjects (92.3%) reported 35 TEAEs; in the 10 mg group, 10 subjects (90.9%) experienced 36 TEAEs; in the 15 mg group, 12 subjects (100.0%) reported 57 TEAEs. In the positive control group, 12 subjects (75.0%) experienced 28 TEAEs, and in the placebo group, 8 subjects (66.7%) had 22 TEAEs. Gastrointestinal AEs were primarily diarrhoea and abdominal distension. In the 5 mg dose group, five subjects (38.5%) experienced five diarrhoea events and three subjects (23.1%) experienced three abdominal distension events; in the 10 mg dose group, four subjects (36.4%) experienced four diarrhoea events and three subjects (27.3%) experienced four abdominal distension events; in the 15 mg dose group, nine subjects (75.0%) experienced nine diarrhoea events and three subjects (25.0%) experienced three abdominal distension events; in the semaglutide 1 mg group, one subject (6.3%) experienced one diarrhoea event and one subject (6.3%) experienced one abdominal distension event; in the placebo group, one subject (8.3%) experienced one abdominal distension event and no diarrhoea was recorded. No hypoglycaemia events were recorded. A total of 37 subjects (57.8%) experienced AEs related to the study drug, including those considered ‘definitely related’, ‘likely related’ or ‘possibly related’, with 92 instances reported. In the 5 mg dose group, 10 subjects (76.9%) experienced 20 related AEs; in the 10 mg group, 7 subjects (63.6%) had 20 related events; in the 15 mg group, 10 subjects (83.3%) experienced 33 related AEs. In the semaglutide 1 mg group, 6 subjects (37.5%) had 9 related AEs, and in the placebo group, 4 subjects (33.3%) reported 10 related events. There were two serious AEs (SAEs) (3.1%), with a total of two occurrences. In the 5 mg dose group, one participant experienced a ruptured cerebral aneurysm leading to intracranial haemorrhage. This subject had a confirmed history of cerebral aneurysm, and after discussion with the investigator, it was concluded that this SAE was related to the subject's medical history and not the study drug. In the 10 mg dose group, one subject experienced an SAE of left lower limb pain. The investigator determined that this SAE was possibly unrelated to the study drug. One participant experienced an AE that led to treatment discontinuation and withdrawal from the trial. No suspected unexpected serious adverse reactions (SUSARs) were reported. A summary of the AEs was provided in Appendix SD.1. Immunogenicity Analysis In the 5 mg group, 13 subjects were included in the SS. At baseline, no subjects were ADA positive. After the 4th target dose administration, 3 subjects were ADA positive; after the 8th target dose administration, 1 subject was ADA positive, and after the 12th target dose administration, 1 subject was ADA positive. No subjects were NAb‐positive. In the 10 mg group, 11 subjects were included in the SS. At baseline, 1 subject was ADA positive. After the 4th target dose administration, 2 subjects were ADA positive; after the 8th target dose administration, 3 subjects were ADA positive, and after the 12th target dose administration, 5 subjects were ADA positive. No subjects were NAb‐positive. In the 15 mg group, 12 subjects were included in the SS. At baseline, no subjects were ADA positive. After the 4th target dose administration, 1 subject was ADA positive; after the 8th target dose administration, 3 subjects were ADA positive, and after the 12th target dose administration, 3 subjects were ADA positive. No subjects were NAb‐positive. Based on the fact that the BGM0504 injection is a peptide drug, its structure differs to some extent from that of the human protein. Immunogenicity test results showed that a small number of subjects in the 5 mg, 10 mg and 15 mg dose groups began to develop ADA antibodies 6–10 weeks after administration (4 weeks of target dose treatment). However, as the duration of administration increased, the proportion of ADA‐positive subjects did not show a significant increase. NAb testing of ADA‐positive blood samples showed that no NAb neutralising antibodies were generated. The subjects who developed ADA antibodies did not affect efficacy, nor were any immunogenicity‐related safety issues observed. The immunogenicity characteristics of the BGM0504 injection will be further observed in subsequent Phase III clinical studies. Discussion This randomised, controlled and double‐blind Phase II clinical study aimed to evaluate the safety, tolerability, PKs, PD and immunogenicity of BGM0504 injection at doses of 5, 10 and 15 mg in Chinese adult patients with type 2 diabetes. The study compared the efficacy and safety of BGM0504 injection to semaglutide. The demographic and baseline characteristics of participants across treatment groups were generally well‐balanced, and good medication adherence was observed throughout the study. This study demonstrated that BGM0504 injection at doses of 5, 10 and 15 mg had glucose‐lowering effects over the 12‐week treatment period. All doses effectively reduced HbA1c levels compared to placebo, with reductions that exceeded those observed in the active control group, particularly in the 15 mg dose group. These results suggested that BGM0504, particularly at the 15 mg dose, provided a potent reduction in HbA1c, demonstrating a dose‐dependent effect and comparable, if not superior, efficacy to semaglutide, making it a promising treatment option for managing blood glucose levels in type 2 diabetes. Secondary efficacy outcomes also showed significant improvements in fasting glucose, postprandial glucose, glycaemic control rates and weight loss in the higher dose groups, with results comparable to or slightly better than the active control, which is consistent with an early report [19]. The safety profile of BGM0504 was favourable across all doses, with most AEs being mild to moderate in severity and resolving without intervention. Gastrointestinal‐related AEs were the most commonly reported and occurred primarily during the dose‐titration phase and early stages of maintenance dosing, with tolerability improving over time. No hypoglycaemia or unexpected AEs were observed. However, this study also has a few limitations. First, it lacks sufficient statistical power. This is a Phase IIa exploratory study aimed at preliminarily exploring efficacy and safety signals to inform the design of confirmatory studies. The sample size was determined primarily based on feasibility rather than statistical power calculations. Second, the study duration is relatively short. A 12‐week administration of the target dose is considered sufficient to evaluate the preliminary glucose‐lowering efficacy and safety of the investigational drug. Nevertheless, longer‐term benefits, such as weight reduction, cardiovascular improvement and safety risks associated with chronic use, will need to be assessed in subsequent Phase III studies with up to 52 weeks of treatment. In summary, the findings of this study suggested that BGM0504 injection was both effective and well‐tolerated, making it a strong candidate for further development in Phase III clinical trials for the treatment of type 2 diabetes. Optimising the dose‐titration period in future studies may further enhance its safety and tolerability. Funding This study is sponsored by BrightGene Innovative Bio‐Medical Technology (Wuxi) Co. Ltd. Conflicts of Interest Y.H., H.D., D.X., X.Y. and J.Y. are employees of BrightGene Bio‐Medical Technology Co. Ltd, and might own stock/stock options in the company. Z.C. and H.Z. are current or former employee of Beijing Noahpharm Medical Technology Co. Ltd, a contract research organization that was contracted by the sponsor to perform the study. P.J., L.J. and X.J. declare no conflicts of interest. Supporting information Data S1: Supporting Information.